MRVI vs. AMRX, CPRX, BHC, OGN, MIRM, XENE, IBRX, GMTX, ARWR, and APLS
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs. Its Competitors
Maravai LifeSciences (NASDAQ:MRVI) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
In the previous week, Maravai LifeSciences had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Maravai LifeSciences and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.95 beat Maravai LifeSciences' score of 0.77 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Amneal Pharmaceuticals has a net margin of -0.46% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Amneal Pharmaceuticals' return on equity.
Maravai LifeSciences currently has a consensus price target of $6.64, indicating a potential upside of 160.86%. Amneal Pharmaceuticals has a consensus price target of $11.60, indicating a potential upside of 41.03%. Given Maravai LifeSciences' higher possible upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Amneal Pharmaceuticals.
Amneal Pharmaceuticals has higher revenue and earnings than Maravai LifeSciences. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Maravai LifeSciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Summary
Amneal Pharmaceuticals beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 7/16/2025 by MarketBeat.com Staff
